Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms

NCT ID: NCT06801639

Last Updated: 2025-08-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-15
• Study Completion Date: 2028-12-31

Brief Summary

Participants will be asked to participate in this research study of a device that creates transcranial direct current stimulation (tDCS).

The researchers hope to learn if 30 minute sessions of transcranial direct current stimulation (tDCS) improve such a mood or feelings in people with Alzheimer's Disease.

This study involves the use of an investigational device called a tDC stimulator. "Investigational" means that the device has not yet been approved by the U.S. Food & Drug Administration (FDA) for treating Alzheimer's Disease.

This study will help find out what effects, good and/or bad, this has. The safety of this device in humans has been tested in prior research studies; however, some side effects may not yet be known.

Detailed Description

Three in-person visits will occur: (1) on the week prior to the first day of stimulation visit patients will undergo brain MRI scan to collect T1, T2, DWI and resting state functional MRI (rs-fMRI), and functional Near-Infrared Spectroscopy/Electroencephalography (fNIRS/EEG) imaging. In this visit, patients and caregivers will be taught how to operate the tDCS device and will receive a unit to take home; (2) on the day after completing the first treatment period, patients will undergo a second MRI scan with the same sequences and fNIRS/EEG imaging; (3) on the day after completing the second treatment period, at the end of week 5, patients will return the tDCS device to the study team and perform a last fNIRS/EEG imaging.

At in-person visits and during treatment periods patients will be asked questions regarding tolerability and acceptability, including monitoring for side effects, as well as completing questionnaires that assess cognition and NPS. All sessions will be remotely supervised via video conference platform.

Conditions

Alzheimer Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Active TDCS treatment

The active-tDCS treatment will consist of a constant 2mA current applied during 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation.

Group Type: EXPERIMENTAL

Transcranial direct current stimulation (tDCS)

Intervention Type: DEVICE

The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.

Sham TDCS treatment

Sham-tDCS treatment will consist of the same montage but the electric current will be applied only in the first and final 30s of stimulation.

Group Type: SHAM_COMPARATOR

Sham tDCS

Intervention Type: DEVICE

Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.

Interventions

Transcranial direct current stimulation (tDCS)

The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.

Intervention Type: DEVICE

Sham tDCS

Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.

Intervention Type: DEVICE

Other Intervention Names

tDCS; Control

Eligibility Criteria

Inclusion Criteria

1. individuals aged 18-85 years with confirmed HD mutation and/or established family history alongside typical symptoms (i.e., chorea) of HD;

2. early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn criteria, also known as the UHDRS total functional capacity (TFC) scale (Bates, Tabrizi, and Jones 2014);

3. exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4;

4. stable doses of medications for at least one month.

5. Ability of subject to understand and the willingness to sign a written informed consent document.

6. Have a caregiver willing to be present during tDCS sessions and answer questionnaires.

Caregiver

1. An adult who serves as an unpaid caregiver for an individual enrolled in the study as interpreted by the PI or delegate physician.

2. Adequate cognitive capacity to provide verbal consent to participate in the caregiver arm of the study.

3. Adequate reading, writing, hearing, and verbal capacity to provide collateral information about the study participant as well as answer questions related to their health and care.

Exclusion Criteria

1. Unstable medical conditions (e.g. unstable angina, uncontrolled diabetes and hypertension, advanced cancer, etc.);

2. History of epilepsy;

3. Clinical diagnosis of major cognitive disorder (i.e., dementia);

4. Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening (Posner et al. 2011);

5. Being an active participant in other therapeutic clinical trial;

6. Determined to be incapable of consent per PMH or via assessment by the study staff at time of consent.

7. Participant has a pacemaker or any other implanted device/material contraindicated in the use of tDCS per current labeling requirements.

Caregiver

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alzheimer's Association

OTHER

Sponsor Role: collaborator

The University of Texas Health Science Center at San Antonio

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thiago Macedo e Cordeiro, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Locations

University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Thiago Macedo e Cordeiro, MD, MSc

Role: CONTACT

macedoecorde@uthscsa.edu

210-450-8418

Antonio L Teixeira, MD, PhD

Role: CONTACT

teixeiraa@uthscsa.edu

210-450-8636

Facility Contacts

Thiago Macedo e Cordeiro, MD, MSc

Role: primary

macedoecorde@uthscsa.edu

210-450-8418

Antonio L Teixeira, MD, PhD

Role: backup

teixeiraa@uthscsa.edu

210-450-8636

Other Identifiers

STUDY00001032

Identifier Type: -

Identifier Source: org_study_id